多西紫杉醇联合表阿霉素新辅助化疗治疗三阴性乳腺癌与非三阴性乳腺癌的疗效比较

目的比较多西紫杉醇联合表阿霉素对三阴性乳腺癌和非三阴性乳腺癌的新辅助化疗的疗效及毒副反应。方法 172例乳腺癌患者接受多西紫杉醇联合表阿霉素方案新辅助化疗,比较观察该方案对三阴性乳腺癌与非三阴性乳腺癌的疗效及毒副反应的差别。结果 172例患者中,59例（34.3%）为三阴性乳腺癌,113（65.7%）例为非三阴性乳腺癌。172例患者的总有效率为85.5%,其中临床完全缓解率为34.9%,病理完全缓解率为23.8%。三阴性乳腺癌的临床完全缓解率（47.5%）、病理完全缓解率（44.1%）明显高于非三阴性乳腺癌（28.3%、13.3%）（P〈0.05）。三阴性乳腺癌的5 a无病生存率和5 a总生存率分别为54.2%和76.3%,低于非三阴性乳腺癌的80.5%和94.7%（P〈0.05）。结论多西紫杉醇联合表阿霉素方案用于乳腺癌的新辅助化疗安全有效,三阴性乳腺癌更易获得近期疗效,而非三阴性乳腺癌远期疗效较好。

Comparison of Efficacy of Docetaxel plus Epirubicin in the Neoadjuvant Chemotherapy of Triple Negative Breast Cancer and Non-triple Negative Breast Cancer

Objective To compare the efficacy and toxicities of docetaxel plus epirubicin in the neoadjuvant chemotherapy of patients with triple negative breast cancer and non-triple negative breast cancer. Methods One hundred and seventy-two patients with breast cancer were treated with docetaxel plus epirubicin neoadjuvant chemotherapy,the efficacy and toxicities for triple negative breast cancer and non-triple negative breast cancer were compared. Results Of the 172 patients,59 patients（ 34. 3%） were triple negative breast cancer and 113 patients（ 65.7%） were non-triple negative breast cancer. The overall response rate was 85. 5%（ 147/172）,the clinical complete response rate was 34. 9%,the pathological complete response rate was 23. 8%. The clinical complete response rate and the pathological complete response rate（ 47. 5% and 44. 1%） in the triple negative breast cancer were higher than those（ 28. 3% and 13. 3%） of the non-triple negative breast cancer（ P 〈 0. 05）. The 5-year disease free survival rate and the 5-year overall survival rate（ 54. 2% and 76. 3%） in the triple negative breast cancer were higher than those（ 80. 5% and 94. 7%） of the non-triple negative breast cancer（ P〈 0. 05）. Conclusion Docetaxel plus epirubicin is safe and effect in the neoadjuvant chemotherapy of patients with breast cancer,has the better short-term efficacy for the triple negative breast cancer,and has the better long-term efficacy for non-triple negative breast cancer.